According to Jefferies, NuVasive NUVA reported a 1Q result that beat on both revenue and earnings.
Jefferies said that the revenue beat was driven by better performance out of the core lumbar business; the EPS beat was mostly non-operational. “The spine market remains challenging, but the outlook appears to be stabilizing. NUVA is exceeding its targets and guidance remains readily achievable. Reiterate Buy.”
NuVasive closed yesterday at $30.60.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in